Gilbert Y Wong
Overview
Explore the profile of Gilbert Y Wong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
1205
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Harding J, Garrido-Laguna I, Chen X, Basu C, Dowlati A, Forgie A, et al.
Front Immunol
. 2022 May;
13:845417.
PMID: 35493516
Clinical Trial Registration: URL: https://clinicaltrials.gov/ct2/show/NCT02659631, ClinicalTrials.gov Identifier: NCT02659631.
2.
Jhaveri K, Burris Rd H, Yap T, Hamilton E, Rugo H, Goldman J, et al.
Expert Rev Anticancer Ther
. 2021 Jun;
21(10):1105-1124.
PMID: 34176404
The cell cycle cyclin-dependent kinases (CDKs) play a critical role in controlling the transition between cell cycle phases, as well as cellular transcription. Aberrant CDK activation is common in cancer,...
3.
Williams J, Udata C, Ganguly B, Bucktrout S, Joh T, Shannon M, et al.
AAPS J
. 2020 Jan;
22(2):23.
PMID: 31900603
IL-7 receptor-α (IL-7Rα) blockade has been shown to reverse autoimmune diabetes in the non-obese diabetic mouse by promoting inhibition of effector T cells and consequently altering the balance of regulatory...
4.
George G, Barata P, Campbell A, Chen A, Cortes J, Hyman D, et al.
Cancer Treat Rev
. 2019 May;
76:33-40.
PMID: 31108240
Attribution of adverse events (AEs) is critical to oncology drug development and the regulatory process. However, processes for determining the causality of AEs are often sub-optimal, unreliable, and inefficient. Thus,...
5.
King G, Eaton K, Beagle B, Zopf C, Wong G, Krupka H, et al.
Invest New Drugs
. 2018 Jan;
36(5):836-847.
PMID: 29333575
Purpose and Methods Trop-2 is a glycoprotein over-expressed in many solid tumors but at low levels in normal human tissue, providing a potential therapeutic target. We conducted a phase 1...
6.
Olesen A, Kristensen K, Staahl C, Kell S, Wong G, Arendt-Nielsen L, et al.
Clin Pharmacokinet
. 2012 Dec;
52(2):125-37.
PMID: 23212610
Background: Peripherally acting opioids, particularly peripheral κ-opioid agonists, may be effective for treating visceral pain by activating receptors expressed on afferent nerves within the gut. Objective: The objective of this...
7.
Arendt-Nielsen L, Olesen A, Staahl C, Menzaghi F, Kell S, Wong G, et al.
Anesthesiology
. 2009 Aug;
111(3):616-24.
PMID: 19672186
Background: Peripherally selective opioids may be beneficial in visceral pain management due to absence of centrally mediated side effects. The objectives of this study were: (1) to assess the effects...
8.
Wong G, Gavva N
Brain Res Rev
. 2009 Jan;
60(1):267-77.
PMID: 19150372
The vanilloid receptor TRPV1 is a homotetrameric, non-selective cation channel abundantly expressed in the nociceptors (c-fibers). TRPV1 is considered as a highly validated pain target because, i) its agonists such...
9.
Cheville A, Sloan J, Northfelt D, Jillella A, Wong G, Bearden Iii J, et al.
Support Care Cancer
. 2009 Jan;
17(4):451-60.
PMID: 19142669
Objective: Current therapies often have limited efficacy and untenable side effects when used to treat persistent incisional pain following cancer-related surgery. Lidocaine patches reduce neuropathic pain from herpes zoster but...
10.
Rao R, Flynn P, Sloan J, Wong G, Novotny P, Johnson D, et al.
Cancer
. 2008 Apr;
112(12):2802-8.
PMID: 18428211
Background: Lamotrigine, an antiepileptic agent, has been reported as being effective in reducing symptoms of neuropathy associated with various etiologies. Based on such data, a multicenter double-blind, placebo-controlled, randomized trial...